…
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -87.77M | -130.76M | -124.24M | -352.45M | 6.12M |
| Minority interest | 0.00M | 0.44M | -0.24M | 0.24M | - |
| Net income | -68.62M | -108.44M | -105.14M | -337.26M | 10.89M |
| Selling general administrative | 71.10M | 77.03M | 108.23M | 82.44M | 30.38M |
| Selling and marketing expenses | 21.14M | 20.88M | 19.09M | 16.65M | 3.52M |
| Gross profit | 65.05M | 111.17M | 165.44M | 157.21M | 30.16M |
| Reconciled depreciation | 55.93M | 57.12M | 54.72M | 49.32M | - |
| Ebit | -31.18M | -83.88M | -81.22M | -322.75M | 7.80M |
| Ebitda | 24.75M | -26.76M | -26.51M | -273.42M | 15.37M |
| Depreciation and amortization | 55.93M | 57.12M | 54.72M | 49.32M | 7.56M |
| Operating income | -30.90M | -86.41M | -81.46M | -27.45M | 1.53M |
| Other operating expenses | 543.93M | 577.14M | 653.88M | 575.10M | 95.22M |
| Interest expense | 56.59M | 46.88M | 43.02M | 29.70M | 1.68M |
| Tax provision | -19.14M | -21.88M | -19.34M | -15.19M | - |
| Net interest income | -56.59M | -46.88M | -43.02M | -29.70M | - |
| Income tax expense | -19.14M | -21.88M | -19.34M | -15.19M | -4.78M |
| Total revenue | 513.02M | 490.74M | 572.42M | 547.66M | 89.61M |
| Total operating expenses | 95.95M | 197.58M | 246.90M | 184.66M | 35.77M |
| Cost of revenue | 447.97M | 379.57M | 406.98M | 390.44M | 59.45M |
| Total other income expense net | -56.87M | -44.35M | -42.78M | -89.00M | 0.50M |
| Net income from continuing ops | -68.62M | -108.89M | -104.90M | -337.26M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 771.11M | 781.36M | 856.53M | 962.90M | 321.86M |
| Intangible assets | 240.20M | 274.40M | 308.43M | 345.89M | 24.23M |
| Other current assets | 29.67M | 46.37M | 31.79M | 42.95M | 21.13M |
| Total liab | 635.09M | 610.86M | 588.04M | 603.13M | 216.73M |
| Total stockholder equity | 136.03M | 170.50M | 269.15M | 360.37M | 105.13M |
| Other current liab | 64.61M | 23.81M | 57.87M | 103.24M | 8.93M |
| Common stock | 8.55M | 6.47M | 6.41M | 6.36M | 3.94M |
| Capital stock | 8.55M | 6.47M | 6.41M | 6.36M | - |
| Retained earnings | -630.81M | -562.16M | -453.28M | -348.28M | -11.02M |
| Good will | 94.29M | 94.29M | 94.29M | 157.82M | 51.93M |
| Cash | 21.74M | 21.43M | 35.49M | 18.52M | 138.92M |
| Total current liabilities | 556.78M | 119.04M | 132.19M | 164.10M | 55.11M |
| Current deferred revenue | 51.51M | 41.99M | 18.93M | 68.64M | 26.61M |
| Net debt | 481.89M | 423.69M | 382.15M | 367.98M | 35.27M |
| Short term debt | 412.51M | 15.31M | 18.23M | 30.96M | 13.39M |
| Short long term debt | 405.12M | 3.54M | 7.95M | 22.98M | - |
| Short long term debt total | 503.63M | 445.12M | 417.64M | 386.49M | 174.19M |
| Other stockholder equity | 756.06M | 724.79M | 715.70M | 707.79M | 112.20M |
| Total current assets | 194.59M | 163.41M | 213.80M | 232.98M | 189.02M |
| Net receivables | 97.45M | 77.44M | 90.42M | 100.07M | 28.36M |
| Long term debt | - | 389.80M | 369.80M | 330.68M | - |
| Inventory | 45.74M | 18.17M | 56.10M | 71.44M | 0.60M |
| Accounts payable | 48.53M | 33.53M | 32.56M | 28.70M | 6.16M |
| Accumulated other comprehensive income | 2.23M | 1.41M | 0.33M | -5.50M | 0.00M |
| Non currrent assets other | 7.32M | 5.69M | 6.40M | 7.52M | 0.28M |
| Non current assets total | 576.52M | 617.95M | 642.73M | 729.92M | 132.84M |
| Capital lease obligations | 54.16M | 52.43M | 39.90M | 32.84M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total cashflows from investing activities | -12.89M | -16.83M | -28.75M | -333.72M | -54.06M |
| Net borrowings | -1.95M | 13.55M | 17.93M | 214.26M | - |
| Total cash from financing activities | 23.70M | 9.68M | 15.87M | 203.15M | 198.83M |
| Net income | -68.62M | -108.89M | -104.90M | -337.26M | 10.89M |
| Change in cash | 0.31M | -14.06M | 16.51M | -137.94M | 155.52M |
| Begin period cash flow | 21.43M | 35.49M | 18.98M | 156.92M | 1.41M |
| End period cash flow | 21.74M | 21.43M | 35.49M | 18.98M | 156.92M |
| Total cash from operating activities | -10.46M | -6.80M | 27.88M | -5.22M | 10.75M |
| Issuance of capital stock | 27.52M | 0.00M | 0.00M | 0.00M | - |
| Depreciation | 55.93M | 57.12M | 54.72M | 49.32M | 6.27M |
| Other cashflows from investing activities | 3.72M | 5.48M | -2.37M | 0.29M | 0.00M |
| Change to inventory | -27.59M | 38.21M | 14.01M | -35.20M | 0.10M |
| Change to account receivables | -3.83M | 14.17M | 9.55M | -23.84M | -11.95M |
| Other cashflows from financing activities | -1.88M | -3.87M | 0.03M | -11.11M | -5.98M |
| Capital expenditures | 16.61M | 22.31M | 27.50M | 36.30M | 12.47M |
| Change in working capital | -1.14M | 52.60M | 16.96M | -40.28M | 9.64M |
| Stock based compensation | 6.03M | 6.74M | 7.84M | 24.20M | 1.79M |
| Other non cash items | 18.97M | 8.87M | 79.08M | 316.63M | -12.86M |
| Free cash flow | -27.07M | -29.11M | 0.38M | -41.52M | -1.73M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
-17.51 2.54% |
671.24 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.25 0.11% |
220.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.77 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.92 3.87% |
22.85 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert W. Leasure Jr. | President, CEO & Director | 1960 |
| Ms. Beth A. Taylor CPA | EVP & CFO | 1965 |
| Ms. Andrea M. Castetter | EVP of General Counsel & Corporate Secretary and Chief Compliance Officer | 1978 |
| Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. | Chief Strategy Officer & Director | 1966 |
| Dr. Adrian Hardy Ph.D. | Chief Commercial Officer | 1971 |
| Mr. Brennan Freeman | VP of Finance, Principal Accounting Officer & Corporate Controller | 1987 |
| Mr. John Gregory Beattie DSA | Chief Operating Officer of DSA | 1967 |
| Ms. Lizanne Muller | Group President of RMS | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.